Pánczél, G.; Horváth, P.; Temaj, E.; Czirbesz, K.; Kispál, M.T.; Fröhlich, G.; Balatoni, T.
Real-World Outcomes of Ipilimumab–Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study. Cancers 2025, 17, 3521.
https://doi.org/10.3390/cancers17213521
AMA Style
Pánczél G, Horváth P, Temaj E, Czirbesz K, Kispál MT, Fröhlich G, Balatoni T.
Real-World Outcomes of Ipilimumab–Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study. Cancers. 2025; 17(21):3521.
https://doi.org/10.3390/cancers17213521
Chicago/Turabian Style
Pánczél, Gitta, Patrik Horváth, Erijona Temaj, Kata Czirbesz, Mihály Tamás Kispál, Georgina Fröhlich, and TÃmea Balatoni.
2025. "Real-World Outcomes of Ipilimumab–Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study" Cancers 17, no. 21: 3521.
https://doi.org/10.3390/cancers17213521
APA Style
Pánczél, G., Horváth, P., Temaj, E., Czirbesz, K., Kispál, M. T., Fröhlich, G., & Balatoni, T.
(2025). Real-World Outcomes of Ipilimumab–Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study. Cancers, 17(21), 3521.
https://doi.org/10.3390/cancers17213521